Page 144 - 71_04

JUAN TAMARGO AN. R. ACAD. NAC. FARM.

NIEMINEN, M. S.; BOHM, M.; COWIE, M. R., DREXLER, H.; FILIPPATOS, G. S., JONDEAU, G.,
et al.: ESC Committe for Practice Guideline (CPG) (2005). Executive summary
of the guidelines on the diagnosis and treatment of acute heart failure: the Task
Force on Acute Heart Failure of the European Society of Cardiology. Eur. Heart
J. 26: 384-416.

PITT, B.; REMME, W.; ZANNAD. F.; NEATON, J.; MARTINEZ, F.; RONIKER, B., et al. (2003):
Eplerenone, a selective aldosterone blocker, in patients with left ventricular
dysfunction after myocardial infarction. N. Engl. J. Med. 348: 1309-1321.

Fibrilación auricular

ALLESIE, M.; BOYDEN, P.; CAMM, J., et al. (2001): Pathophysiology and prevention of
atrial fibrillation. Circulation. 103: 769-777.

FUSTER, V.; RYDÉN, L. E.; ASINGER, R. W., et al. (2001): ACC/AHA/ESC guidelines for
the management of patients with atrial fibrillation: Executive summary. J. Am.
Coll. Cardiol. 38: 1231-1265.

NATTEL, S.; LI, D. y YUE L. (2000): Basic mechanism of atrial fibrillation. Very new
insights into very old ideas. Annu. Rev. Physiol. 62: 51-77.

NATTEL, S. (2002): New ideas about atrial fibrillation 50 years on. Nature. 415: 219-
226.

NATTEL, S.; KHAIRY, P.; ROY, D., et al. (2002): New approaches to atrial fibrillation
management: a critical review of a rapidly evolving field. Drugs. 62, 2377-2397.

SINGH, B. (1999): Current antiarrhythmic drugs: an overview of mechanisms of
action and potential clinical utility. J. Cardiovasc. Electrophysiol. 10: 283-301.

TAMARGO, J.; CABALLERO, R. y DELPÓN, E. (2004): Pharmacological approaches in the
treatment of atrial fibrillation. Curr. Med. Chem. 11: 13-28.

TAMARGO, J. (2000): A review: Drug-induced torsades de pointes: from molecular
biology to bedside. Jap. J. Pharmacol. 83: 1-19.

TAMARGO, J. y ALMENDRAL, J. (1999): Pharmacologic Treatment of Arrhythmias. En:
Cardiology. Eds. Dalla Volta, S.; Bayés, A.; Brochier, M.; Dienstl, F.; Jezek, V.;
Mortensen, S.; Poole-Wilson, P.; Braunwald, E. McGraw-Hill, Londres: 255-262.

Stents

BAVRY, A. A.; KUMBHANI, D. J.; HELTON, T. J. y BHATT, D. L. (2005): What is the risk
of stent thrombosis associated with the use of paclitaxel-eluting stents for per-
cutaneous coronary intervention?: a meta-analysis. J. Am. Coll. Cardiol. 45: 941-
946.

BHARGAVA, B.; KARTHIKEYAN, G. A. S.; ABIZAID, A. S. y MEHRAN, R. (2003): New appro-
aches to preventing restenosis. Br. Med. J. 327: 274-279.

GERSHLICK, A. H. (2005): Drug eluting stents in 2005. Heart. 91 (Suppl 3): 24-31.
SCHWARTZ, R. S.; CHRONOS, N. A. y VIRMANI, R. (2003): Preclinical restenosis models

and drug-eluting stents: still important, still much to learn. J. Am. Coll. Cardiol.
44: 1373-1385.

946